XML 86 R19.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one operating segment, the research and development of its investigational drug product. The Company used the management approach to determine its reportable operating segment. The Company's Chief Operating Decision Maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The Company is a clinical-stage pharmaceutical company and has limited revenue associated with a license and collaboration agreement. The CODM uses net loss as a measure of profit and loss, and assesses Company performance through the achievement of its clinical development goals. The CODM is regularly provided with budgeted and forecasted expense information which is used to determine the Company’s liquidity needs and cash allocation to its development programs. The CODM uses cash and marketable securities as a measure of segment assets in managing the enterprise.
The Company had revenue of $70 thousand and $70 thousand for the three and six months ended June 30, 2025, respectively, and $0 and $0 for the three and six months ended June 30, 2024, respectively. Depreciation and amortization expense was $44 thousand and $87 thousand for the three and six months ended June 30, 2025, respectively and $45 thousand and $91 thousand for the three and six months ended June 30, 2024, respectively. Equity method investment expense was $0 and $0 for the three and six months ended June 30, 2025, respectively, and $0 and $100 thousand for the three and six months ended June 30, 2024, respectively.
The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three and six months ended June 30, 2025 and 2024:

 Three Months Ended June 30,Six Months Ended June 30,
 2025202420252024
Revenue$70 $— $70 $— 
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial605 1,075 1,393 2,345 
  ASCEND trial32 94 53 138 
  Chemistry, manufacturing and controls167 284 387 939 
  Clinical department991 1,056 2,148 2,190 
  Other (1)
458 92 875 230 
Research and development2,253 2,601 4,856 5,842 
General and administrative by significant expense:
  Corporate1,157 1,272 2,302 2,404 
  Investor relations/public relations/communications309 347 640 632 
  Finance538 585 1,167 1,165 
  Legal327 239 551 909 
  Business development140 145 267 317 
  Share based compensation expense212 200 616 568 
  Other (2)
2 134 387 287 
General and administrative2,685 2,922 5,930 6,282 
Operating loss(4,868)(5,523)(10,716)(12,124)
Other income, net209 479 371 881 
Benefit from income taxes— — (962)(798)
Net loss$(4,659)$(5,044)$(9,383)$(10,445)
Cash and marketable securities$21,970 $38,262 
 (1) Included in Other are the GBM study,
     FORTIFIDE study and research oncology
     expenses
 (2) Included in Other are facilities expense, human
     resource and information technology expenses